S2 Table. Supportive and anti-viral medications in the early remdesivir and late remdesivir-cohort

|                                | No remdesivir (n=107) | Early remdesivir (n=107) | Late remdesivir (n=109) | P-value |
|--------------------------------|-----------------------|--------------------------|-------------------------|---------|
| COVID-19 severity status®      | 51 (48)               | 17 (16)                  | 24 (22)                 | 0.001   |
| Supportive medications#        |                       |                          |                         |         |
| Tocilizumab                    | 55 (51)               | 36 (34)                  | 42 (38)                 | 0.024   |
| Antiviral medications*         |                       |                          |                         |         |
| Favipiravir                    | 20 (19)               | 8 (8)                    | 14 (13)                 | 0.051   |
| Interferon beta-1b             | 19 (18)               | 10 (10)                  | 10 (11)                 | 0.088   |
| Interferon beta-1b and favipiravir | 19 (18)               | 7 (7)                    | 16 (15)                 | 0.042   |
| Interferon beta-1b, lopinavir–ritonavir, and ribavirin | 13 (12)               | 5 (5)                    | 10 (9)                  | 0.147   |
| Lopinavir–ritonavir            | 12 (11)               | 4 (4)                    | 8 (7)                   | 0.114   |

Data are n (%). © COVID-19 severity status is defined as a COVID-19 pneumonia requiring high-flow oxygen therapy or non-invasive ventilation. # All the patients received systemic corticosteroids including dexamethasone 6 mg daily, or methylprednisolone with 2 mg/kg/day starting dose and max 60 mg/day for pulse dosing. *Antiviral therapies before the initiation of remdesivir. Abbreviation: COVID-19, coronavirus disease 2019.